Compare Heron Therapeutics Inc (HRTX) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Las Vegas Sands Corp. — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $68.01M), while Las Vegas Sands Corp. trades at $36.46 (market cap $23.38B). The key difference: Las Vegas Sands Corp. is far larger — about 343.8× Heron Therapeutics Inc's market cap, and Las Vegas Sands Corp. pays a 3.32% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Las Vegas Sands Corp. for 72 Days on average.
| HRTX | LVS | |
|---|---|---|
Market Cap | $68.01M | $23.38B |
Volume | 1,891,941 | 6,994,661 |
Sector | Health | Consumer Cyclical |
52-Week High | $1.49 | $69.49 |
52-Week Low | $0.27 | $35.81 |
Typical Hold Time | 35 Days | 72 Days |
Enterprise Value | $174.75M | $35.27B |
Dividend Yield | — | 3.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
LVS trades at $35.81, down 1.38% today, with a bearish technical signal despite bullish oscillators. The company shows strong fundamentals with 2025 revenue of $13.02B and net income of $1.63B, supported by consistent earnings beats in recent quarters. Analyst consensus remains strongly bullish with 59% buy ratings and a $59.78 price target, representing 67% upside potential from current levels.
LVS presents compelling value with attractive valuation multiples (P/E 13.99, EV/EBITDA 7.64) and robust profitability (ROE 134.29%). Key risks include high debt levels (debt-to-asset ratio 73.15%) and sensitivity to Macao gaming regulations. The stock's current discount to analyst targets offers significant upside if operational momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
